|
Items |
Date Initiated |
Concurrent therapy with intravenous pemetrexed and cisplatin administration Lung Cancer
(Only cases judged to have been completely excised pathologically excluding squamous lung cancer and small cell lung cancer) |
Sep. 1,2012 |
Percutaneous radiofrequency ablation (RFA) (Breast cancer) |
Aug. 1,2013 |
A multicenter randomized phase Ⅲ study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab (JCOG1308C, RE-GEND-pⅢ) |
Jan. 1,2018 |
Phase Ⅲ Study of High-dose Methotrexate and Whole Brain Rdiotherapy With or Without Concomitant and Adjuvant Temozolomide in Patients with Primary CNS Lymphoma (JCOG1114C, PCNSL-TMZ-P3) |
Jan. 1,2018 |
Multiplex genetic panel test Advanced or recurrent cancers (For the cases of unresectable carcinoma due to far advancement or for the cases of post-operative recurrence with unknown origin or with no standard therapeutic regimens; limited to the cases who have actually or almost ended with conventional therapies) |
Aug. 1,2018 |
MRI/Ultrasound Fusion Prostate Biopsy
(Patients with suspected prostate cancer) |
Oct. 1,2019 |
hydorgen inhalation therapy |
May. 1,2020 |
|